FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/09/2024
Back to search
Official data from USPTO
ARECOR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
11/09/2024
Trademark type
Word
Nice classes
5, 42
Filing date
09/28/2021
Registration date
04/23/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/23/2024
Last transaction
04/23/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
KLUWE, CHERYL
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Arecor Limited
Representatives
Amanda M. Prose Westman, Champlin & Koehler, P.A.
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical preparationsdiagnostic preparations for medical purposespreparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularmetabolicimmune-oncologyoncologyanti-infectiveneurosciencecardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmologyrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersrare diseasesautoimmuneinflammatoryimmunologypaininfectious diseasesrenalreproductive health and childbirthblood disordersvaccineshaematological related diseases and disorders; Medicinal productspharmaceutical products for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularmetabolicimmune-oncologyoncologyanti-infectiveneurosciencecardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmologyrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersrare diseasesautoimmuneinflammatoryimmunologypaininfectious diseasesrenalreproductive health and childbirthblood disordersvaccineshaematological related diseases and disorders; Pharmaceuticalspreparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularmetabolicimmune-oncologyoncologyanti-infectiveneurosciencecardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmologyrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersrare diseasesautoimmuneinflammatoryimmunologypaininfectious diseasesrenalreproductive health and childbirthblood disordersvaccineshaematological related diseases and disorders; Biopharmaceuticalspreparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularmetabolicimmune-oncologyoncologyanti-infectivesneurosciencecardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmologyrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersrare diseasesautoimmuneinflammatoryimmunologypaininfectious diseasesrenalreproductive health and childbirthblood disordersvaccineshaematological related diseases and disorders
Class 42
Medical and pharmacological research services; consultancy in the field of pharmaceutical research and development; development of pharmaceutical preparations and medicines; pharmaceutical product evaluation and development; research and development of vaccines and medicines
Publications
History of USPTO decisions and trademark events.
38 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/22/2024
FIMP
FINAL DISPOSITION PROCESSED
10/21/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/24/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/23/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/23/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/06/2024
PUBO
PUBLISHED FOR OPPOSITION
02/06/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/05/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/17/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/17/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/17/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/22/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/22/2023
ALIE
ASSIGNED TO LIE
11/22/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/20/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/22/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/03/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/03/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/16/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/16/2023
CNSL
SUSPENSION LETTER WRITTEN
03/16/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/15/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/13/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/13/2023
RFNP
REFUSAL PROCESSED BY IB
10/03/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/14/2022
RFRR
REFUSAL PROCESSED BY MPU
09/13/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/05/2022
CNRT
NON-FINAL ACTION WRITTEN
08/04/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
07/28/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/30/2022
CNRT
NON-FINAL ACTION WRITTEN
06/29/2022
DOCK
ASSIGNED TO EXAMINER
06/28/2022
MAFR
APPLICATION FILING RECEIPT MAILED
12/07/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/03/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/02/2021
Continuous trademark protection
Get notified about every new filing that threatens ARECOR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.